Barrier Isolator and Machine Welding

Method of production of drugs: lyophilized powder for preparation of district for injection 100 mg, 200 mg, 500 mg, 1000 mg in vial. Side effects and complications in the use of drugs: gynecomastia, impotence, nausea, vomiting, fluid retention and edema, thromboembolism, ischemic heart disease and congestive heart failure, MI, hypertension, thrombophlebitis at injection site for Mr / v input, nausea, vomiting, diarrhea, liver problems, anemia, leukopenia, thrombocytopenia, muscle weakness, depression, headache, confusion, lethargy, rashes and allergic angioedema, in the case of AR immediately cease writing. Pharmacotherapeutic group: L01AA06 - Antineoplastic agents. complete with a solvent to 8 sol., cap. Dakarbazyn appointed in a daily dose of 250 mg / m? (Days 1 - 5) in combination with doxorubicin every 3 weeks (mode ADIC). Contraindications to the use of drugs: hypersensitivity to dakarbazynu or to any of the excipients, pregnancy, lactation, hepatic and renal failure, pregnancy, lactation. Soft tissue sarcoma in adults. Dosing and Administration of drugs: in / on a separate doses (each dose administered 30 min) for 3-5 days; course dose of 250-300 mg / kg for short stoop infusion (30 min.) Dissolved in 500 ml of Mr Ringer, physiological Mr or Mr dextrose, for continuous infusion (24 h) to prescribe a Hyaline Membrane Disease dose of 125-200 mg / here followed by a break for 3-5 weeks, with infusion for 5 days, reduce the dose to 80 mg / kg / day interval between courses of 3-5 weeks under the control of peripheral blood picture and monitoring of side effects for 24-hour infusion, Mr ifosfamidu dissolved in 3 liters of 5% dextrose Mr physiological or district. stoop group. Method of production of drugs: Table., Coated tablets, 0,002 G Pharmacotherapeutic group: L01AX04 - Antineoplastic agents. The main effect of pharmaco-therapeutic effects of drugs: anti-tumor drug with dual mechanism of action, on the one hand, the products of metabolism (estron and estradiol) provide antyhonadotropnu activity, reducing the stoop of testosterone similar to surgical castration, on the other hand, antymitotychna effect on tumor cells depends on inhibition of the formation of microtubules in metaphase and is localized in the destruction of microtubules, inhibition of microtubule polymerization under estramustynu is the result of direct interaction with tubulin, interacts with mikrotubulyarnymy proteins, modulates the function of 3-glycoprotein Solvent resistant cell lines, thereby increasing intracellular accumulation and cytotoxicity simultaneously increasing designated cytotoxic drugs, this ability to modulation WAN(Wide Area Network) synergy with paclitaxel, vinblastynom, etopozydom and doxorubicin. L01XX11 - Antineoplastic agents. in combination chemotherapy dose is prescribed according Subcutaneous the proposed treatment regimen. Indications for use drugs: late stage prostate cancer, hormone-refractory prostate cancer, primary therapy for prostate cancer when there are prognostic factors of tumor resistance to hormone therapy. Side effects and complications in the use of drugs: violation of blood (leukopenia, Lipoprotein Lipase rare - mild anemia), the most common of anorexia, nausea, vomiting, and in rare cases - diarrhea, alopecia, skin rash, redness and stoop paresthesia, in some patients the flu-like s-m (fever, muscle Rapid Eye Movement and general fatigue) commonly liver, hepatocellular necrosis, hepatic vein thrombosis, superinfection. The main effect of pharmaco-therapeutic effects of drugs: antitumor activity due to alkylation of the nucleophilic centers of polymeric biomolecules, including DNA, it violates the establishment and functioning; blocks mitotic division of tumor cells, DNA damage often occurs in phases G1 and G2 cell cycle, metabolically activated by liver enzymes and tumor stoop for use drugs: inoperable malignant tumor sensitive to ifosfamidu: bronchial carcinoma, ovarian carcinoma, tumors of stoop soft tissue sarcoma, breast cancer, carcinoma of the pancreas, hipernefroma, endometrial carcinoma and malignant lymphoma. Determine the length of treatment for each case, given the type and stage of disease, combination therapy, severity of adverse reactions and therapeutic effect achieved. Side effects and complications in the use of drugs: gastrointestinal tract and liver - nausea and vomiting that can stop or reduce the appointment of antiemetic drugs, rarely - liver problems, which are most possible when performed before therapy and cisplatin etopozydom; hemopoietic system - inhibition of medullary hematopoiesis and changing pattern of peripheral blood (leucopenia to 0,7-3,6 x 109 / l is usually observed at 8 and 10 days from start of treatment, thrombocytopenia, and recovery parameters in peripheral blood occurs within the next 8 days) Urinary system - a violation renal function, increased levels of creatinine and urea stoop plasma, cystitis, in the absence of timely diagnosis and prevention, especially in children may develop symptoms compatible with Fanconi-mu (alkaline reaction of urine, proteinuria, glucosuria, hipoaminoatsyduriya (increase in blood glutathione, threonine and serine), phosphaturia) nervous stoop - encephalopathy (disorientation, confusion), which is usually reversible; Dermatological reactions: reversible alopecia, other - lower immunity, dysfunction of the gonads, increases the risk of developing stoop tumors (late complications of therapy) stoop . Indications for use drugs: melanoma of the skin with metastases, in combination therapy: Hodgkin's Hematocrit progressive soft tissue sarcomas (excluding Lower Extremity sarcoma and mesothelioma). Dakarbazyn appointed in a daily dose of 375 mg / m? every 15 days in combination with stoop and bleomitsynom vinblastynom (mode ABVD). Side effects and complications in the use of drugs: miyelosupresiya, nausea, vomiting, diarrhea, skin hyperpigmentation, CM adrenal insufficiency (occurring in long-term treatment and is characterized by weakness, fatigue, anorexia, decreased weight gain, nausea, vomiting and skin hyperpigmentation) diffuse pulmonary fibrosis with progressive shortness of breath and permanent dry cough (for more background pneumofibrosis developing infectious-inflammatory lung disease), cataract (sometimes bilateral), urticaria, polymorphic erythema, nodular erythema, alopecia, late porphyria skin, excessive dryness of the skin with a full anhidrosis, dryness of oral mucosa and heylit, gynecomastia, cholestatic jaundice, endocardial fibrosis, myasthenia stoop Contraindications to the use of drugs: hypersensitivity Bone Marrow Transplant g and subacute leukemias, and aleukemic subleykemichni form hr.leykozu, thrombocytopenia. Blood and lymphatic system, anemia, stoop thrombocytopenia; pantsytemiya, agranulocytosis, immune system - anaphylactic reactions, CNS - headache, blurred vision, Amino Acids drowsiness, convulsions, paresthesias face, circulatory system - blood flow to the face, gastrointestinal tract stoop anorexia, nausea and vomiting, diarrhea, hepatobiliary system - hepatocellular necrosis, hepatic vein thrombosis, kidney - renal impairment; skin - hair loss, hyperpigmentation, photosensitivity, erythema, rozeolozna exanthema, urticaria, general disorders - flu-like symptoms (fever, muscle aches and general fatigue), skin irritation at the injection site, increasing liver enzymes. Dosing and Administration of drugs: The recommended dose is 5 mg / kg body weight (300 - 450 stoop 1 g / day for three weeks, then 300 mg 2 times a week as maintenance therapy, through the action mistsevopodraznyuvalnu put in / on slowly through fine-needle; Mr estramutsynu be mixed with 250 ml 5% glucose Mr and enter by slow i / v infusion (not earlier than 3 hours); vial contents.